WuXi Diagnostics

WuXi Diagnostics is an innovative platform company in the field of diagnostics, which combines multi-omics clinical data from multidisciplinary technologies with algorithms

WuXi's mission is to build an innovative model that enables diagnostic product innovation, generates clinical insights, and benefits the health of mankind through precision diagnosis and treatment.

WuXi Diagnostics was founded in 2018 and is headquartered in Shanghai, Shanghai, China. WuXi has an R&D center at Mayo Clinic headquarters in Rochester, U.S.

WuXi is providing multidisciplinary technology solutions to improve health care practice and advance patient care.

WuXi has a rich product pipeline in many disease indications. The company's efficient innovation transformation capability and international cooperation ability gives us confidence for its rapid development in the future.

 

WuXi's core product, Enabling Solution Package (ESP), is a disease-focused total solution with advanced testing panels, medical paradigm and algorithms for disease diagnosis, and insightful medical content based on real-world clinical evidence.

 

WuXi has raised $150M in a Series B round on Feb 23, 2021. Backers included Thermo Fisher Scientific Inc., Shiyu Capital, YF Capital, ABC International Holdings Limited and others.

 

 

  • Year founded: 2018
  • Funding Info: $150M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: NA
  • City/Town: Shanghai
  • State: Shanghai
  • Country: China
Related businesses